Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Stifel 2025 Virtual CNS Forum.
The company's management will engage in a fireside chat scheduled for Wednesday, March 19, 2025, at 9:00 a.m. ET. The presentation will be accessible through a live webcast, with registration available online. Additionally, the webcast will be hosted in the 'Investors' section under 'Events & Presentations' on the company's website, remaining available for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), un'azienda biotecnologica in fase clinica focalizzata su trattamenti basati sulle microglia per malattie neurodegenerative, ha annunciato la sua prossima partecipazione al Stifel 2025 Virtual CNS Forum.
La direzione dell'azienda parteciperà a una chiacchierata informale programmata per mercoledì 19 marzo 2025, alle 9:00 ET. La presentazione sarà accessibile tramite una diretta streaming, con registrazione disponibile online. Inoltre, la diretta sarà ospitata nella sezione 'Investitori' sotto 'Eventi e Presentazioni' sul sito web dell'azienda, rimanendo disponibile per circa 90 giorni dopo l'evento.
Vigil Neuroscience (Nasdaq: VIGL), una empresa biotecnológica en etapa clínica centrada en tratamientos basados en microglía para enfermedades neurodegenerativas, ha anunciado su próxima participación en el Stifel 2025 Virtual CNS Forum.
La dirección de la empresa participará en una charla informal programada para miércoles 19 de marzo de 2025, a las 9:00 a.m. ET. La presentación será accesible a través de una transmisión en vivo, con registro disponible en línea. Además, la transmisión se alojará en la sección 'Inversores' bajo 'Eventos y Presentaciones' en el sitio web de la empresa, permaneciendo disponible durante aproximadamente 90 días después del evento.
Vigil Neuroscience (Nasdaq: VIGL), 신경퇴행성 질환을 위한 미세아교세포 기반 치료에 중점을 둔 임상 단계의 생명공학 회사가 Stifel 2025 Virtual CNS Forum에 참여할 예정이라고 발표했습니다.
회사의 경영진은 2025년 3월 19일 수요일, 오전 9시 (ET)에 예정된 대화에 참여할 것입니다. 프레젠테이션은 라이브 웹캐스트를 통해 접근 가능하며, 온라인 등록이 가능합니다. 또한, 웹캐스트는 회사 웹사이트의 '투자자' 섹션 아래 '이벤트 및 프레젠테이션'에서 호스팅되며, 이벤트 후 약 90일 동안 이용 가능합니다.
Vigil Neuroscience (Nasdaq: VIGL), une entreprise de biotechnologie en phase clinique axée sur les traitements basés sur les microglies pour les maladies neurodégénératives, a annoncé sa prochaine participation au Stifel 2025 Virtual CNS Forum.
La direction de l'entreprise participera à une discussion informelle prévue pour mercredi 19 mars 2025, à 9h00 ET. La présentation sera accessible par le biais d'un webinaire en direct, avec une inscription disponible en ligne. De plus, le webinaire sera hébergé dans la section 'Investisseurs' sous 'Événements et Présentations' sur le site web de l'entreprise, et restera disponible pendant environ 90 jours après l'événement.
Vigil Neuroscience (Nasdaq: VIGL), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf mikroglia-basierte Behandlungen für neurodegenerative Erkrankungen konzentriert, hat seine bevorstehende Teilnahme am Stifel 2025 Virtual CNS Forum bekannt gegeben.
Die Unternehmensleitung wird an einem informellen Gespräch teilnehmen, das für Mittwoch, den 19. März 2025, um 9:00 Uhr ET geplant ist. Die Präsentation wird über einen Live-Stream zugänglich sein, mit Online-Registrierung. Darüber hinaus wird der Stream im Bereich 'Investoren' unter 'Veranstaltungen & Präsentationen' auf der Unternehmenswebsite gehostet und bleibt etwa 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Wednesday, March 19, 2025, at 9:00 a.m. ET.
To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When is Vigil Neuroscience (VIGL) presenting at the Stifel 2025 Virtual CNS Forum?
How can investors access VIGL's presentation at the Stifel CNS Forum?
How long will VIGL's Stifel CNS Forum presentation recording be available?
What is the focus of Vigil Neuroscience's (VIGL) research and development?
